Browse studies

Find your next paid study

135 recruiting studies matching your filters

TEMPUS ONCO-OLIVIA Registry

This study entails enrolling participants that have been diagnosed with cancer to Olivia, a commercially available AI-enabled personal health platform develope…

CancerSolid Tumor CancerPediatric Acute Myeloid Leukemia+1 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Tempus AINCT07756034

Phase 1

A Phase I Trial to Evaluate the Safety and Efficacy of Addition of Novel Anti-leukemia Agents to Flu/Mel RIC Transplant for High-risk Myeloid Malignancies

The purpose of this study is to determine the safety of adding Decitabine and Venetoclax to patients undergoing reduced intensity allogenic transplantation for…

Myeloid MalignancyHematologic MalignancyAcute Myeloid Leukemia+1 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

University of Alabama at BirminghamNCT07044544

Study of Precursor Hematological Malignancies to Assess the Relationship Between Molecular Events of Progression and Clinical Outcome

Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the ca…

Monoclonal Gammopathy of Undetermined Significance (MGUS)Myelodysplastic SyndromesHematological Malignancies+5 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Dana-Farber Cancer InstituteNCT02269592

Phase 2

Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies

To determine the safety and efficacy (1-year PFS) of iC9/CD5CAR/IL-15 NK cells as consolidation in patients with aggressive T-cell malignances in first remissi…

Hematological Malignancies

Estimated

~$75 – $2,000

Actual pay is set by the research site.

M.D. Anderson Cancer CenterNCT07137481

Observational

A Multi-component Non-pharmacological Intervention to Improve Cognitive Outcomes in Hematologic Cancer Survivors

The goal of this clinical trial is to examine feasibility of a cognitive intervention program in blood cancer survivors. The main questions it aims to answer a…

Cognitive ImpairmentHematologic Malignancy

Estimated

~$10 – $750

Actual pay is set by the research site.

University of Alabama at BirminghamNCT05708716

Collection of Whole Blood and Tissue Specimens From Patients Diagnosed With Non-Hematologic Cancer for Use in Development of a Noninvasive Liquid Biopsy Assay to Determine the Tumor Genomic Profile in Circulating Cell-Free Tumor DNA

This specimen collection is designed to obtain whole blood and tumor tissue from subjects diagnosed with cancer for the purpose of the development of a noninva…

Non-hematologic Cancer

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Sequenom, Inc.NCT02586389

Observational

Allogeneic Hematopoietic Stem Cell Transplantation From an HLA-partially Matched Related or Unrelated Donor After TCR αβ+T Cells/CD19+ B Cell Depletion in Children and Young Adults Affected by Malignant or Non-Malignant Hematological Disorders

The purpose of the CliniMACS® TCRαβ-Biotin System and CliniMACS® CD19 is to improve the safety and efficacy of allogeneic HLA-partially matched related or unre…

Hematologic Diseases

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Alice BertainaNCT04249830

Umbilical Cord Blood Transplantation From Unrelated Donors

This study is being done to determine how long it takes for the engraftment (recovery of blood cell counts) of umbilical cord stem cells and also how often eng…

Acute LeukemiaImmune Deficiency DisorderCongenital Hematological Disorder+7 more

Estimated

~$10 – $750

Actual pay is set by the research site.

University of RochesterNCT03016806

Phase 1

A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hemato…

Relapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AMLOther IDH1-mutated Positive Hematologic Malignancies+1 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Institut de Recherches Internationales ServierNCT02074839

Genomic Profiling in Cancer Patients

The purpose of this study is to determine whether certain genes in cancer may be abnormal. When a gene is abnormal this is called a mutation. Most mutations in…

Solid TumorsHematologic Cancers

Estimated

~$10 – $750

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT01775072

Phase 1

Addition of Venetoclax to Combined Reduced Intensity Hematopoietic Stem Cell and Kidney Transplantation for Patients With Chronic Kidney Disease and Hematologic Malignancy

The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC a…

Kidney Failure ChronicStem Cell TransplantStem Cell Transplant Complications+2 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Massachusetts General HospitalNCT07358195

Phase 1

A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed/Refractory Multiple Myeloma.

The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cel…

Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasms+11 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

OriCell Therapeutics Co., Ltd.